Stockreport
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Narrower Than Expected Loss in Q2, Nil Sales Allogene incurred an adjusted loss (excluding impairment of long-lived assets) of 32 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 35 cents. Inclusive of impairment charges, the company posted a loss of 35 cents in the second quarter. In the year-ago period, the company reported a loss of 54 cents. No impairment charge was recorded during the year-ago period. ALLO did not generate any revenues during the quarter. In the year-ago period, management recorded revenues worth $0.02 million. Quarter in Detail Research & development (R&D) expenses were $50.4 million, down
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence[GlobeNewswire]
- Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies [Seeking Alpha][Seeking Alpha]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.[MarketBeat]
- Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Citigroup Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
ALLO
SEC Filings
SEC Filings
- 8/23/24 - Form 4
- 8/21/24 - Form 144
- 8/7/24 - Form 10-Q
- ALLO's page on the SEC website
- More